Skip NavigationSkip to Content
Return Return to Search Results

Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET

  1. Author:
    Huang, F.
    Ma, Z.
    Pollan, S.
    Yuan, X.
    Swartwood, S.
    Gertych, A.
    Rodriguez, M.
    Mallick, J.
    Bhele, S.
    Guindi, M.
    Dhall, D.
    Walts, A. E.
    Bose, S.
    de Peralta Venturina, M.
    Marchevsky, A. M.
    Luthringer, D. J.
    Feller, S. M.
    Berman, B.
    Freeman, M. R.
    Alvord, W. G.
    Vande Woude, G.
    Amin, M. B.
    Knudsen, B. S.

  2. Author Address

    Department of Biomedical Sciences Cedars-Sinai Medical Center Los Angeles California 90048 USA.;Departments of Surgery Cedars-Sinai Medical Center Los Angeles California 90048 USA.;Department of Pathology and Laboratory Medicine Cedars-Sinai Medical Center Los Angeles California 90048 USA.;Institute of Molecular Medicine, Martin-Luther-University 06120 Halle Germany.;Department of Biomedical SciencesCedars-Sinai Medical CenterLos AngelesCalifornia90048USA; Departments of SurgeryCedars-Sinai Medical CenterLos AngelesCalifornia90048USA; Cancer Biology Program, Departments of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical CenterLos AngelesCalifornia90048USA.;Data Management Services, Inc., National Cancer Institute at Frederick Frederick Maryland 21702 USA.;Laboratory of Molecular Oncology Center for Cancer and Cell Biology, Van Andel Research Institute Grand Rapids Michigan 49503 USA.;Department of Biomedical SciencesCedars-Sinai Medical CenterLos AngelesCalifornia90048USA; Department of Pathology and Laboratory MedicineCedars-Sinai Medical CenterLos AngelesCalifornia90048USA.
    1. Year: 2016
    2. Date: Oct
    3. Epub Date: 10/28/2016
  2. Journal: The journal of pathology. Clinical research
    1. 2
    2. 4
    3. Pages: 210-222
  4. Type of Article: Article
  5. ISSN: 2056-4538
  1. Abstract:

    The limited clinical success of anti-HGF/MET drugs can be attributed to the lack of predictive biomarkers that adequately select patients for treatment. We demonstrate here that quantitative digital imaging of formalin fixed paraffin embedded tissues stained by immunohistochemistry can be used to measure signals from weakly staining antibodies and provides new opportunities to develop assays for detection of MET receptor activity. To establish a biomarker panel of MET activation, we employed seven antibodies measuring protein expression in the HGF/MET pathway in 20 cases and up to 80 cores from 18 human cancer types. The antibodies bind to epitopes in the extra (EC)- and intracellular (IC) domains of MET (MET4EC, SP44_METIC, D1C2_METIC), to MET-pY1234/pY1235, a marker of MET kinase activation, as well as to HGF, pSFK or pMAPK. Expression of HGF was determined in tumour cells (T_HGF) as well as in stroma surrounding cancer (St_HGF). Remarkably, MET4EC correlated more strongly with pMET (r = 0.47) than SP44_METIC (r = 0.21) or D1C2_METIC (r = 0.08) across 18 cancer types. In addition, correlation coefficients of pMET and T_HGF (r = 0.38) and pMET and pSFK (r = 0.56) were high. Prediction models of MET activation reveal cancer-type specific differences in performance of MET4EC, SP44_METIC and anti-HGF antibodies. Thus, we conclude that assays to predict the response to HGF/MET inhibitors require a cancer-type specific antibody selection and should be developed in those cancer types in which they are employed clinically.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1002/cjp2.49
  3. PMID: 27785366
  4. PMCID: PMC5068192

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel